Mouse Models of IM
IM小鼠模型
基本信息
- 批准号:7912880
- 负责人:
- 金额:$ 44.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:Abnormal CellBone MarrowCellsDefectDevelopmentDiseaseDisease ProgressionEmperipolesisExtramedullaryExtramedullary HematopoiesisGenerationsGoalsHematologic NeoplasmsHematopoiesisHematopoieticHematopoietic stem cellsHumanInvestigationMegakaryocytesMembraneMesenchymal Stem CellsModelingMusMyelofibrosisMyeloproliferative diseaseOsteoblastsPatientsPeptide HydrolasesPrimary MyelofibrosisResearchSideSiteStagingStem cellsStromal Cell-Derived Factor 1SystemTestingcell typedrug developmenthuman GATA1 proteinmouse modelneutrophilperipheral bloodstemtooltraffickingtreatment strategy
项目摘要
We propose to use the GATA-1low murine model as a tool to define the biologic mechanisms underlying the
abnormal hematopoietic stem cell (HSC) and progenitor cell (HPC) trafficking and extramedullary
hemopoiesis that characterizes idiopathic myelofibrosis (IM) and identify new targets for the development of
drugs to treat this disorder. During this project we will test the hypothesis that HSC/HPC mobilization occurs
at specific stages of the disease and that abnormal cell trafficking requires either the generation of a specific
cell type (the extramedullary hematopoietic initiating cell, EMH-IC) or mobilization of both HSC/EPC and
mesenchymal stem cells (MSC) and/or endothelial progenitor cells (EPC), responsible for generating a
permissive hematopoietic microenvironment in a variety of extramedullary sites. To test this hypothesis we
will:
Specific Aim 1) To characterize the degree of HSC/HPC and MSC/EPC mobilization and trafficking during
the course of the development of myelofibrosis in GATA-1low mice.
Specific Aim 2) To identify the mechanisms underlying the development of abnormal HSC/HPC trafficking
and extramedullary hemopoiesis in GATA-1low mice.
Specific Aim 3) To identify treatment strategies for the treatment of each stage of the disease in GATA-1low
mice.
Relevance: IM is a hematological malignancy associated with abnormal stem cell trafficking and increased
extramedullary hematopoiesis. We believe that a side-by-side investigation of the mechanisms leading to
abnormal HSC/HPC trafficking and extramedullary hematopoiesis in the mouse model (Project 4) and IM
patients (Project 5) will represent a powerful and effective approach to identify the optimal treatment for IM.
我们建议使用加塔-1 low小鼠模型作为工具,以确定潜在的生物学机制,
异常造血干细胞(HSC)和祖细胞(HPC)运输和髓外
造血,特发性骨髓纤维化(IM)的特点,并确定新的目标,
治疗这种疾病的药物。在本项目中,我们将测试HSC/HPC动员发生的假设
在疾病的特定阶段,异常的细胞运输需要产生特定的
细胞类型(髓外造血起始细胞,EMH-IC)或HSC/EPC和
间充质干细胞(MSC)和/或内皮祖细胞(EPC),负责产生一种或多种细胞因子。
允许的造血微环境中的各种髓外网站。为了验证这一假设,
将:
具体目的1)为了表征HSC/HPC和MSC/EPC动员和运输的程度,
加塔-1 low小鼠骨髓纤维化的发展过程。
具体目的2)确定异常HSC/HPC运输发展的潜在机制
和加塔-1 low小鼠髓外造血。
具体目的3)确定治疗加塔-1低中疾病各阶段的治疗策略
小鼠
相关性:IM是一种与异常干细胞运输相关的血液恶性肿瘤,
髓外造血我们认为,对导致
小鼠模型中的异常HSC/HPC运输和髓外造血(项目4)和IM
患者(项目5)将代表一个强大而有效的方法,以确定最佳的治疗IM。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Anna Rita Rita Migliaccio其他文献
Anna Rita Rita Migliaccio的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Anna Rita Rita Migliaccio', 18)}}的其他基金
相似海外基金
REGULATION OF BONE MARROW MESENCHYMAL STEM CELLS BY VCAM1
VCAM1 对骨髓间充质干细胞的调节
- 批准号:
10537391 - 财政年份:2023
- 资助金额:
$ 44.88万 - 项目类别:
Preserving bone marrow niche integrity and function to rejuvenate aged hematopoietic stem cells
保护骨髓生态位的完整性和功能,使老化的造血干细胞恢复活力
- 批准号:
10735925 - 财政年份:2023
- 资助金额:
$ 44.88万 - 项目类别:
Determination of chronic or intractable mechanisms induced by low bone quality with osteomacs and bone marrow derived stem cells interaction
确定低骨质量诱导的慢性或难治性机制与骨瘤和骨髓干细胞相互作用
- 批准号:
23K18364 - 财政年份:2023
- 资助金额:
$ 44.88万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
The role of abnormal bone marrow progenitor cells and bone marrow mobilization in multiple organ disfunction syndrome.
异常骨髓祖细胞和骨髓动员在多器官功能障碍综合征中的作用。
- 批准号:
23K08424 - 财政年份:2023
- 资助金额:
$ 44.88万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Elucidation of the pathogenesis of peritoneal dissemination of gastric cancer focusing on bone marrow-derived suppressor cells and overcoming resistance to therapy
阐明胃癌腹膜播散的发病机制,重点关注骨髓源性抑制细胞和克服治疗耐药性
- 批准号:
23K15520 - 财政年份:2023
- 资助金额:
$ 44.88万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanism of maintaining hematopoietic stem cells by newly identified bone marrow mesenchymal stem cells.
阐明新鉴定的骨髓间充质干细胞维持造血干细胞的机制。
- 批准号:
23H02935 - 财政年份:2023
- 资助金额:
$ 44.88万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Tissue Engineering of 3D bone marrow niche for hematopoietic stem cells vs acute myeloid leukemia stem cell molecular target and therapeutics discovery
造血干细胞 3D 骨髓生态位的组织工程与急性髓系白血病干细胞分子靶标和治疗发现
- 批准号:
468535 - 财政年份:2022
- 资助金额:
$ 44.88万 - 项目类别:
Operating Grants
New treatment method using improved bone marrow mesenchymal stem cells for pediatric femoral head necrosis
使用改良骨髓间充质干细胞治疗小儿股骨头坏死的新方法
- 批准号:
22K09363 - 财政年份:2022
- 资助金额:
$ 44.88万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Efferocytosis by Bone Marrow Stromal Cells and Bone Aging
骨髓基质细胞的胞吞作用和骨老化
- 批准号:
10629389 - 财政年份:2022
- 资助金额:
$ 44.88万 - 项目类别:
Development of novel treatments and elucidation of mechanisms for intractable epilepsy using bone marrow mesenchymal stem cells
利用骨髓间充质干细胞开发顽固性癫痫的新疗法并阐明其机制
- 批准号:
22K07938 - 财政年份:2022
- 资助金额:
$ 44.88万 - 项目类别:
Grant-in-Aid for Scientific Research (C)